GLIPTIN-M is indicated as an adjunct to diet and exercise to improve glycemic control with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.
Mode of Action
Sitagliptin Sitagliptin is a DPP-4 inhibitor, is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. Metformin Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose.
Sitagliptin Sitagliptin is rapidly absorbed, with peak plasma concentrations (median Tmax) occurring 1 to 4 hours post dose. The absolute bioavailability of sitagliptin is approximately 87%. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. In patients with moderate and severe renal insufficiency, as well as in ESRD patients requiring dialysis, lower dosages are recommended. Metformin Metformin is negligibly bound to plasma proteins. Metformin is excreted unchanged in the urine and does not undergo hepatic metabolism nor biliary excretion.
Dosage and Recommendation
For type-2 diabetes: once daily
Packing and Presentation
Each strip contains 10 tablets in box of 10 × 10s